comparemela.com

Latest Breaking News On - The hospital of university pennsylvania - Page 1 : comparemela.com

ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Mutated Diffuse Midline Gliomas

The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.

North carolinaUnited statesUniversity of pennsylvaniaUniversity of north carolinaStephen bagleyAshley sumrallHospital of the university pennsylvaniaUniversity of north carolina chapel hillAbramson cancer centerAtrium health carolinas medical centerAtrium health levine cancer instituteInternal medicineMedical oncologyNorth carolina chapel hillPhase studies paveData shows tolerable safety profile

Dr Takvorian on the Evolution of PARP Inhibitors in Prostate Cancer

Samuel U. Takvorian, MD, MS, discusses the evolution of regulatory decisions regarding the use of PARP inhibitors for patients with prostate cancer.

Samuelu takvorianHospital of the university pennsylvaniaThe hospital of university pennsylvaniaParp inhibitors for patients with prostate cancer

Dr Narayan on the Evolving Treatment Paradigm in Metastatic Urothelial Carcinoma

Vivek K. Narayan, MD, MS, discusses potential avenues for treatment considerations in patients with metastatic urothelial carcinoma.

Vivekk narayanHospital of the university pennsylvaniaPenn medicineThe hospital of university pennsylvaniaPatients with metastatic urothelial carcinoma

vimarsana © 2020. All Rights Reserved.